Abstract
Road traffic crashes are a leading cause of morbidity and mortality in large cities. Cities including New York City (NYC) in the United States (US) have implemented a suite of interventions to reduce road traffic crashes. Leading pedestrian intervals (LPIs) are a low-cost physical environmental intervention premised to reduce vehicle-pedestrian crashes by providing pedestrians a head-start over the turning vehicular traffic. Using a spatial ecological panel design, we assessed the impact of LPIs on the risk of total, non-fatal, and fatal pedestrian injuries in NYC from January 2013 to December 2018. For the 36,102 intersection-years studied and 6,017 intersections (2,883 LPI-treated) included in the study, there were 26,033 total injuries of which 291 were fatal. Significant reductions were observed for total (19.4% [95% CI: 11.8%, 26.4%]) and non-fatal injuries (19.6% [11.9%, 26.5%]) but not for fatal injuries. Multiple sensitivity analyses ensured robustness of findings. LPIs may prove to be an effective intervention to improve pedestrian safety outcomes across cities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Research reported in this presentation was supported by the Centers for Disease Control and Prevention (CDC) National Center for Injury Prevention and Control Injury Control Research Center Grant R49CE003094. ELE is supported by the National Institutes of Health (NIH), National Institute on Drug Abuse grant T32DA031099. The findings and conclusions in this presentation are those of the authors and do not necessarily represent the views of the CDC or NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
